These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 38898473)

  • 1. Reciprocal regulation between RACGAP1 and AR contributes to endocrine therapy resistance in prostate cancer.
    Wang J; Liu H; Yu Z; Zhou Q; Sun F; Han J; Gao L; Dou B; Zhang H; Fu J; Jia W; Chen W; Hu J; Han B
    Cell Commun Signal; 2024 Jun; 22(1):339. PubMed ID: 38898473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination therapy with androgen receptor N-terminal domain antagonist EPI-7170 and enzalutamide yields synergistic activity in AR-V7-positive prostate cancer.
    Hirayama Y; Tam T; Jian K; Andersen RJ; Sadar MD
    Mol Oncol; 2020 Oct; 14(10):2455-2470. PubMed ID: 32734688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ARVib suppresses growth of advanced prostate cancer via inhibition of androgen receptor signaling.
    Liu C; Armstrong CM; Ning S; Yang JC; Lou W; Lombard AP; Zhao J; Wu CY; Yu A; Evans CP; Tepper CG; Li PK; Gao AC
    Oncogene; 2021 Sep; 40(35):5379-5392. PubMed ID: 34272475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer.
    Liu C; Lou W; Zhu Y; Nadiminty N; Schwartz CT; Evans CP; Gao AC
    Clin Cancer Res; 2014 Jun; 20(12):3198-3210. PubMed ID: 24740322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted suppression of AR-V7 using PIP5K1α inhibitor overcomes enzalutamide resistance in prostate cancer cells.
    Sarwar M; Semenas J; Miftakhova R; Simoulis A; Robinson B; Gjörloff Wingren A; Mongan NP; Heery DM; Johnsson H; Abrahamsson PA; Dizeyi N; Luo J; Persson JL
    Oncotarget; 2016 Sep; 7(39):63065-63081. PubMed ID: 27588408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KIF15-Mediated Stabilization of AR and AR-V7 Contributes to Enzalutamide Resistance in Prostate Cancer.
    Gao L; Zhang W; Zhang J; Liu J; Sun F; Liu H; Hu J; Wang X; Wang X; Su P; Chen S; Qu S; Shi B; Xiong X; Chen W; Dong X; Han B
    Cancer Res; 2021 Feb; 81(4):1026-1039. PubMed ID: 33277366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LncRNA PCBP1-AS1-mediated AR/AR-V7 deubiquitination enhances prostate cancer enzalutamide resistance.
    Zhang B; Zhang M; Shen C; Liu G; Zhang F; Hou J; Yao W
    Cell Death Dis; 2021 Sep; 12(10):856. PubMed ID: 34545063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TAS3681, an androgen receptor antagonist, prevents drug resistance driven by aberrant androgen receptor signaling in prostate cancer.
    Yoshida S; Kajiwara D; Seki M; Tayama M; Tanaka Y; Mizutani H; Fujita R; Yamamura K; Okajima S; Asai M; Minamiguchi K
    Mol Oncol; 2024 Aug; 18(8):1980-2000. PubMed ID: 38600681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Critical role of androgen receptor level in prostate cancer cell resistance to new generation antiandrogen enzalutamide.
    Hoefer J; Akbor M; Handle F; Ofer P; Puhr M; Parson W; Culig Z; Klocker H; Heidegger I
    Oncotarget; 2016 Sep; 7(37):59781-59794. PubMed ID: 27486973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the KIF4A/AR Axis to Reverse Endocrine Therapy Resistance in Castration-resistant Prostate Cancer.
    Cao Q; Song Z; Ruan H; Wang C; Yang X; Bao L; Wang K; Cheng G; Xu T; Xiao W; Xiong Z; Liu D; Yang M; Zhou D; Yang H; Chen K; Zhang X
    Clin Cancer Res; 2020 Mar; 26(6):1516-1528. PubMed ID: 31796514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of AR-regulated AFF3 contributes to prostate cancer progression and reduces ferroptosis sensitivity by downregulating ACSL4 based on single-cell sequencing analysis.
    Fan A; Li Y; Zhang Y; Meng W; Pan W; Chen M; Ma Z; Chen W
    Apoptosis; 2024 Oct; 29(9-10):1679-1695. PubMed ID: 38478171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9
    Wang R; Sun Y; Li L; Niu Y; Lin W; Lin C; Antonarakis ES; Luo J; Yeh S; Chang C
    Eur Urol; 2017 Nov; 72(5):835-844. PubMed ID: 28528814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MED12 and CDK8/19 Modulate Androgen Receptor Activity and Enzalutamide Response in Prostate Cancer.
    Andolfi C; Bartolini C; Morales E; Gündoğdu B; Puhr M; Guzman J; Wach S; Taubert H; Aigner A; Eder IE; Handle F; Culig Z
    Endocrinology; 2024 Aug; 165(10):. PubMed ID: 39253786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone acetyltransferase 1 upregulates androgen receptor expression to modulate CRPC cell resistance to enzalutamide.
    Hong Z; Xiang Z; Zhang P; Wu Q; Xu C; Wang X; Shi G; Hong Z; Wu D
    Clin Transl Med; 2021 Jul; 11(7):e495. PubMed ID: 34323404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer-associated fibroblasts promote prostate tumor growth and progression through upregulation of cholesterol and steroid biosynthesis.
    Neuwirt H; Bouchal J; Kharaishvili G; Ploner C; Jöhrer K; Pitterl F; Weber A; Klocker H; Eder IE
    Cell Commun Signal; 2020 Jan; 18(1):11. PubMed ID: 31980029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AR-v7 protein expression is regulated by protein kinase and phosphatase.
    Li Y; Xie N; Gleave ME; Rennie PS; Dong X
    Oncotarget; 2015 Oct; 6(32):33743-54. PubMed ID: 26378044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective degradation of AR-V7 to overcome castration resistance of prostate cancer.
    Liu Y; Yu C; Shao Z; Xia X; Hu T; Kong W; He X; Sun W; Deng Y; Liao Y; Huang H
    Cell Death Dis; 2021 Sep; 12(10):857. PubMed ID: 34548474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bruceantin targets HSP90 to overcome resistance to hormone therapy in castration-resistant prostate cancer.
    Moon SJ; Jeong BC; Kim HJ; Lim JE; Kim HJ; Kwon GY; Jackman JA; Kim JH
    Theranostics; 2021; 11(2):958-973. PubMed ID: 33391515
    [No Abstract]   [Full Text] [Related]  

  • 19. Unique targeting of androgen-dependent and -independent AR signaling in prostate cancer to overcome androgen resistance.
    Lim SC; Jansson PJ; Assinder SJ; Maleki S; Richardson DR; Kovacevic Z
    FASEB J; 2020 Sep; 34(9):11511-11528. PubMed ID: 32713076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Androgen receptor degraders overcome common resistance mechanisms developed during prostate cancer treatment.
    Kregel S; Wang C; Han X; Xiao L; Fernandez-Salas E; Bawa P; McCollum BL; Wilder-Romans K; Apel IJ; Cao X; Speers C; Wang S; Chinnaiyan AM
    Neoplasia; 2020 Feb; 22(2):111-119. PubMed ID: 31931431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.